Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood

Abstract The aim of the study was to analyze the long-term outcome (>20 years) after treatment of posterior fossa medulloblastoma (MB) in childhood. We analyzed data from patients treated for posterior fossa MB between 1974 (introduction of the first international treatment protocol in Norway) an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Radek Frič, Bernt Johan Due-Tønnessen, Tryggve Lundar, Arild Egge, Bård Kronen Krossnes, Paulina Due-Tønnessen, Einar Stensvold, Petter Brandal
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/850132e028984573baf21931abc93e27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:850132e028984573baf21931abc93e27
record_format	dspace
spelling	oai:doaj.org-article:850132e028984573baf21931abc93e272021-12-02T17:52:13ZLong-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood10.1038/s41598-020-66328-82045-2322https://doaj.org/article/850132e028984573baf21931abc93e272020-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-66328-8https://doaj.org/toc/2045-2322Abstract The aim of the study was to analyze the long-term outcome (>20 years) after treatment of posterior fossa medulloblastoma (MB) in childhood. We analyzed data from patients treated for posterior fossa MB between 1974 (introduction of the first international treatment protocol in Norway) and 1987 (when use of radiotherapy was abandoned in children under 4 years of age). Out of 47 children, 24 survived >20 years. At the time of analysis, 16 patients (median age 41 years, range 32–52) were alive (median follow-up 34 years, range 30–42), while 8 patients died 22–41 years (median 31 years) after primary treatment: one late death (after 22 years) was due to tumor recurrence whilst other 7 deaths (after 23 to 41 years) were related to the detrimental effects of the treatment (secondary tumors, stroke, severe epilepsy and depression). Observed 20- and 30-year survival rates were 51% and 44%, respectively. Despite successful treatment of MB in childhood and satisfactory tumor control during the first 20 years following primary treatment, our data indicates that even long-term survivors may die from tumor recurrence. However, the main factors causing late mortality and morbidity in long-term survivors seem to be the complications related to radiotherapy given in childhood.Radek FričBernt Johan Due-TønnessenTryggve LundarArild EggeBård Kronen KrossnesPaulina Due-TønnessenEinar StensvoldPetter BrandalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Radek Frič Bernt Johan Due-Tønnessen Tryggve Lundar Arild Egge Bård Kronen Krossnes Paulina Due-Tønnessen Einar Stensvold Petter Brandal Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
description	Abstract The aim of the study was to analyze the long-term outcome (>20 years) after treatment of posterior fossa medulloblastoma (MB) in childhood. We analyzed data from patients treated for posterior fossa MB between 1974 (introduction of the first international treatment protocol in Norway) and 1987 (when use of radiotherapy was abandoned in children under 4 years of age). Out of 47 children, 24 survived >20 years. At the time of analysis, 16 patients (median age 41 years, range 32–52) were alive (median follow-up 34 years, range 30–42), while 8 patients died 22–41 years (median 31 years) after primary treatment: one late death (after 22 years) was due to tumor recurrence whilst other 7 deaths (after 23 to 41 years) were related to the detrimental effects of the treatment (secondary tumors, stroke, severe epilepsy and depression). Observed 20- and 30-year survival rates were 51% and 44%, respectively. Despite successful treatment of MB in childhood and satisfactory tumor control during the first 20 years following primary treatment, our data indicates that even long-term survivors may die from tumor recurrence. However, the main factors causing late mortality and morbidity in long-term survivors seem to be the complications related to radiotherapy given in childhood.
format	article
author	Radek Frič Bernt Johan Due-Tønnessen Tryggve Lundar Arild Egge Bård Kronen Krossnes Paulina Due-Tønnessen Einar Stensvold Petter Brandal
author_facet	Radek Frič Bernt Johan Due-Tønnessen Tryggve Lundar Arild Egge Bård Kronen Krossnes Paulina Due-Tønnessen Einar Stensvold Petter Brandal
author_sort	Radek Frič
title	Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
title_short	Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
title_full	Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
title_fullStr	Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
title_full_unstemmed	Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
title_sort	long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/850132e028984573baf21931abc93e27
work_keys_str_mv	AT radekfric longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT berntjohanduetønnessen longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT tryggvelundar longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT arildegge longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT bardkronenkrossnes longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT paulinaduetønnessen longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT einarstensvold longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood AT petterbrandal longtermoutcomeofposteriorfossamedulloblastomainpatientssurvivingmorethan20yearsfollowingprimarytreatmentinchildhood
_version_	1718379237261443072

Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood

Ejemplares similares